Pål Hasvold

2.7k total citations · 2 hit papers
33 papers, 1.8k citations indexed

About

Pål Hasvold is a scholar working on Cardiology and Cardiovascular Medicine, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Pål Hasvold has authored 33 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Cardiology and Cardiovascular Medicine, 14 papers in Pulmonary and Respiratory Medicine and 10 papers in Surgery. Recurrent topics in Pål Hasvold's work include Acute Myocardial Infarction Research (10 papers), Antiplatelet Therapy and Cardiovascular Diseases (9 papers) and Heart Failure Treatment and Management (8 papers). Pål Hasvold is often cited by papers focused on Acute Myocardial Infarction Research (10 papers), Antiplatelet Therapy and Cardiovascular Diseases (9 papers) and Heart Failure Treatment and Management (8 papers). Pål Hasvold collaborates with scholars based in Sweden, Norway and Denmark. Pål Hasvold's co-authors include Marcus Thuresson, Tomas Jernberg, Magnus Janzon, Martin Henriksson, Hans Hjelm, Fredrik Wiklund, Magnus Ekström, Christer Janson, Bright I. Nwaru and Gunilla Telg and has published in prestigious journals such as Circulation, PLoS ONE and European Heart Journal.

In The Last Decade

Pål Hasvold

32 papers receiving 1.8k citations

Hit Papers

Cardiovascular risk in po... 2015 2026 2018 2022 2015 2020 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective
    2015 594 citations Tomas Jernberg, Pål Hasvold et al. European Heart Journal profile →
  2. Overuse of short-acting β2-agonists in asthma is associated with increased risk of exacerbation and mortality: a nationwide cohort study of the global SABINA programme
    2020 285 citations Bright I. Nwaru, Magnus Ekström et al. European Respiratory Journal profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Pål Hasvold 889 686 665 337 155 33 1.8k
Lakshmi Venkitachalam 1.5k 1.7× 522 0.8× 619 0.9× 98 0.3× 183 1.2× 34 2.1k
Marinus A. van den Dorpel 389 0.4× 932 1.4× 514 0.8× 170 0.5× 151 1.0× 78 2.9k
Alı Başçı 607 0.7× 1.0k 1.5× 742 1.1× 437 1.3× 234 1.5× 61 3.4k
Sergio Raposeiras‐Roubín 1.7k 1.9× 480 0.7× 192 0.3× 255 0.8× 246 1.6× 188 2.5k
Abhishek Sharma 1.1k 1.2× 425 0.6× 188 0.3× 236 0.7× 104 0.7× 99 1.8k
Agustín Urrútia 1.7k 1.9× 332 0.5× 147 0.2× 322 1.0× 69 0.4× 71 2.5k
Shari Targum 1.3k 1.5× 368 0.5× 242 0.4× 91 0.3× 104 0.7× 13 1.7k
Adrian Covic 525 0.6× 414 0.6× 263 0.4× 173 0.5× 93 0.6× 55 1.8k
Luca Di Lullo 876 1.0× 293 0.4× 399 0.6× 118 0.4× 175 1.1× 112 2.0k
Diem Dinh 1.8k 2.1× 820 1.2× 298 0.4× 71 0.2× 235 1.5× 169 2.4k

Countries citing papers authored by Pål Hasvold

Since Specialization
Citations

This map shows the geographic impact of Pål Hasvold's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pål Hasvold with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pål Hasvold more than expected).

Fields of papers citing papers by Pål Hasvold

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pål Hasvold. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pål Hasvold. The network helps show where Pål Hasvold may publish in the future.

Co-authorship network of co-authors of Pål Hasvold

This figure shows the co-authorship network connecting the top 25 collaborators of Pål Hasvold. A scholar is included among the top collaborators of Pål Hasvold based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Pål Hasvold. Pål Hasvold is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Nwaru, Bright I., Magnus Ekström, Pål Hasvold, et al.. (2020). Overuse of short-acting β2-agonists in asthma is associated with increased risk of exacerbation and mortality: a nationwide cohort study of the global SABINA programme. European Respiratory Journal. 55(4). 1901872–1901872. 285 indexed citations breakdown →
2.
Kytö, Ville, et al.. (2019). Usage of PCI and long-term cardiovascular risk in post-myocardial infarction patients: a nationwide registry cohort study from Finland. BMC Cardiovascular Disorders. 19(1). 123–123. 19 indexed citations
3.
Hasvold, Pål, et al.. (2019). Concomitant use of drugs known to cause interactions with oral antiplatelets—polypharmacy in acute coronary syndrome outpatients in Finland. European Journal of Clinical Pharmacology. 76(2). 257–265. 11 indexed citations
4.
Adelborg, Kasper, Sia Kromann Nicolaisen, Pål Hasvold, et al.. (2019). Predictors for repeated hyperkalemia and potassium trajectories in high-risk patients — A population-based cohort study. PLoS ONE. 14(6). e0218739–e0218739. 31 indexed citations
5.
Ekström, Magnus, Bright I. Nwaru, Pål Hasvold, et al.. (2019). Oral corticosteroid use, morbidity and mortality in asthma: A nationwide prospective cohort study in Sweden. Allergy. 74(11). 2181–2190. 59 indexed citations
6.
Andersson, Manne, Marcus Thuresson, Birgitta Sigvant, et al.. (2018). Editor's Choice – Impact of Comorbidity, Medication, and Gender on Amputation Rate Following Revascularisation for Chronic Limb Threatening Ischaemia. European Journal of Vascular and Endovascular Surgery. 56(5). 681–688. 33 indexed citations
7.
Andersson, Manne, Birgitta Sigvant, Björn Kragsterman, et al.. (2018). Impact of Comorbidity, Medication, and Gender on Amputation Rate Following Revascularisation for Chronic Limb Threatening Ischaemia. Journal of Vascular Surgery. 68(6). 1959–1960. 1 indexed citations
8.
Andersson, Manne, Marcus Thuresson, Birgitta Sigvant, et al.. (2017). Amputation Rates, Mortality, and Pre-operative Comorbidities in Patients Revascularised for Intermittent Claudication or Critical Limb Ischaemia: A Population Based Study. European Journal of Vascular and Endovascular Surgery. 54(4). 480–486. 128 indexed citations
9.
Sigvant, Birgitta, Pål Hasvold, Björn Kragsterman, et al.. (2017). Cardiovascular outcomes in patients with peripheral arterial disease as an initial or subsequent manifestation of atherosclerotic disease: Results from a Swedish nationwide study. Journal of Vascular Surgery. 66(2). 507–514.e1. 52 indexed citations
10.
Varenhorst, Christoph, Saga Johansson, Pål Hasvold, et al.. (2016). Abstract 13206: Culprit and Non-Culprit Recurrent Ischemic Events in Post-Myocardial Infarction Patients: Data From SWEDEHEART. Circulation. 134(suppl_1).
11.
Janzon, Magnus, Martin Henriksson, Pål Hasvold, et al.. (2016). Long-term resource use patterns and healthcare costs after myocardial infarction in a clinical practice setting: results from a contemporary nationwide registry study. European Heart Journal - Quality of Care and Clinical Outcomes. 2(4). 291–298. 18 indexed citations
12.
Sigvant, Birgitta, Björn Kragsterman, Mårten Falkenberg, et al.. (2016). Contemporary cardiovascular risk and secondary preventive drug treatment patterns in peripheral artery disease patients undergoing revascularization. Journal of Vascular Surgery. 64(4). 1009–1017.e3. 87 indexed citations
13.
Halvorsen, Sigrun, Jarle Jortveit, Pål Hasvold, Marcus Thuresson, & Erik Øie. (2016). Initiation of and long-term adherence to secondary preventive drugs after acute myocardial infarction. BMC Cardiovascular Disorders. 16(1). 115–115. 49 indexed citations
14.
Jernberg, Tomas, Pål Hasvold, Martin Henriksson, et al.. (2015). Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective. European Heart Journal. 36(19). 1163–1170. 594 indexed citations breakdown →
15.
Hasvold, Pål, Marcus Thuresson, Johan Sundström, et al.. (2015). Association Between Paradoxical HDL Cholesterol Decrease and Risk of Major Adverse Cardiovascular Events in Patients Initiated on Statin Treatment in a Primary Care Setting. Clinical Drug Investigation. 36(3). 225–233. 12 indexed citations
16.
Svensson, Elisabeth, et al.. (2015). Statin prescription patterns, adherence, and attainment of cholesterol treatment goals in routine clinical care: a Danish population-based study. Clinical Epidemiology. 7. 213–213. 46 indexed citations
17.
Varenhorst, Christoph, Karin Jensevik, Tomas Jernberg, et al.. (2013). Duration of dual antiplatelet treatment with clopidogrel and aspirin in patients with acute coronary syndrome. European Heart Journal. 35(15). 969–978. 38 indexed citations
18.
Henriksson, Martin, David Russell, Johan Bodegård, et al.. (2010). Health-care costs of losartan and candesartan in the primary treatment of hypertension. Journal of Human Hypertension. 25(2). 130–136. 9 indexed citations
19.
Russell, David, Jan Stålhammar, Johan Bodegård, et al.. (2010). Cardiovascular Events in Subgroups of Patients During Primary Treatment of Hypertension With Candesartan or Losartan. Journal of Clinical Hypertension. 13(3). 189–197. 8 indexed citations
20.
Kjeldsen, Sverre E., et al.. (2009). Effects of losartan vs candesartan in reducing cardiovascular events in the primary treatment of hypertension. Journal of Human Hypertension. 24(4). 263–273. 48 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Lakshmi Venkitachalam Breakdown of academic impact, for papers by Marinus A. van den Dorpel Breakdown of academic impact, for papers by Alı Başçı Breakdown of academic impact, for papers by Sergio Raposeiras‐Roubín Breakdown of academic impact, for papers by Abhishek Sharma Breakdown of academic impact, for papers by Agustín Urrútia Breakdown of academic impact, for papers by Shari Targum Breakdown of academic impact, for papers by Adrian Covic Breakdown of academic impact, for papers by Luca Di Lullo Breakdown of academic impact, for papers by Diem Dinh
Rankless by CCL
2026